Related Experiment Video
Updated: May 5, 2026
07:52
Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
Published on: June 2, 2015
12.0K
Preconditioning and metabolic anti-ischaemic agents
1Hatter Institute for Cardiology Research, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa. opie@capeheart.uct.ac.za
European Heart Journal
|October 18, 2003
Summary
Preconditioning protects the heart during ischemia, but avoiding ischemia entirely is best. Certain metabolic agents, while protecting from ischemia, may not precondition but can be beneficial for heart failure therapy.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Preconditioning is a protective response to transient ischemia and reperfusion.
- Avoiding ischemia is the optimal protective strategy.
- Mechanisms of ischemia prevention and preconditioning differ.
Purpose of the Study:
- To explore the relationship between anti-ischemic agents and preconditioning.
- To investigate how metabolic agents affect myocardial protection.
- To assess the therapeutic potential of these agents in ischemia and heart failure.
Main Methods:
- Analysis of metabolic pathways in myocardial protection.
- Investigation of ATP-dependent potassium channels in preconditioning.
- Evaluation of agents like glucose-insulin-potassium, trimetazidine, and ranolazine.
Main Results:
- Metabolically active agents promote glucose metabolism over fatty acid metabolism.
- These agents may close ATP-dependent potassium channels, potentially uncoupling preconditioning.
- They offer mitochondrial protection and oxygen-sparing effects by reducing fatty acid oxidation.
Conclusions:
- Anti-ischemic agents may not precondition, and some pro-ischemic agents might.
- Metabolic agents protect by enhancing glycolysis and sparing oxygen.
- These properties suggest therapeutic utility in myocardial ischemia and heart failure.
More Related Videos
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
01:27Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655